Results 71 to 80 of about 49,818 (236)
Clinical usefulness of cancer markers in primary breast cancer [PDF]
, 2011 The aim of this study was to investigate the diagnostic power of CA 549, MSA and CA 15-3 in identifying breast cancer. The study included 232 patients of which 56 were healthy, 43 had benign breast cancer and 191 with other growths.
Clouth, Aline +3 more
core +2 more sources
The Prostate, EarlyView.ABSTRACT Introduction The clinical relevance of HER2 expression profile in solid cancers has expanded with the evolving landscape of HER2 targeting agents. This systematic review and meta‐analysis aim to detail the prevalence of HER (over)expression in prostate cancer and identify patient/disease subgroups with enriched HER2 overexpression.
Jacky T. F. Luk +10 more
wiley +1 more source
Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis [PDF]
, 2016 Table S1. Characteristics of the included studies.
Jiafeng Shou +4 more
core +3 more sources
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, EarlyView.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Revista Brasileira de Ginecologia e Obstetrícia, 2004 OBJETIVOS: avaliar a variação do grau nuclear e da expressão das proteínas p53 e c-erbB-2 e dos receptores de estrógeno (RE) no carcinoma ductal in situ (CDIS) e no carcinoma invasivo, presentes na mesma mama. MÉTODOS: estudo descritivo retrospectivo com
Orlando José de Almeida +5 more
doaj +1 more source
The basic biology of erbB-2 and its participation in colorectal cancers [PDF]
, 2005 ErbB-2 is one of Tour cell surface growth factor receptors involved in transmission of signals controlling normal cell growth and differentiation. A range of growth factors serve as ligands, but none is specific for the ErbB-2 receptor.
Bryś, Magdalena +2 more
core
Mutations and amplification of oncogenes in endometrial cancer [PDF]
, 1999 Alterations in oncogenes are critical steps in the development of endometrial cancer. To investigate the potential clinical relevance of the amplification of the oncogenes c-erbB2, c-myc, and int-2 and the mutation of K-ras in endometrial cancer, 112 ...
An, Han-Xiang +5 more
core +1 more source
Cardiotoxicity of BRAF/MEK inhibitors
British Journal of Pharmacology, EarlyView.Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren +8 more
wiley +1 more source
乳腺浸润性导管癌c-erbB-2的表达与淋巴结转移和肿瘤细胞分裂能力的关系
Zhongguo shiyan zhenduanxue, 2005 目的探讨乳腺浸润性导管癌中c-erbB-2与肿瘤生物学特性的关系。方法应用免疫组化SP方法对检测乳腺浸润性导管癌c-erbB-2的表达情况极其淋巴结转移和癌细胞分裂能力的相关性。结果c-erbB-2阳性表达主要分布在肿瘤细胞的胞膜上;随着c-erbB-2表达强度的降低,肿瘤淋巴结转移率呈减少的趋势;肿瘤组织中细胞的核分裂数目随着c-erbB-2的表达强度增加而增多。结论c-erbB-2是乳腺癌细胞增殖、转移能力和预后判定的参考指标。
王勇 +5 more
doaj